Shopping Cart
Remove All
Your shopping cart is currently empty
Ontuxizumab (Synonyms: MORAb-004)
Catalog No. T77374 Copy Product Info
🥰Excellent
Ontuxizumab (MORAb-004) is a potent IgG1/κ monoclonal antibody targeting endomelanic acid with anti-tumor effects. It specifically targets endothelin (TEM-1 or CD248) and is used for the treatment of metastatic melanoma.
Ontuxizumab
Copy Product Info🥰Excellent
Catalog No. T77374
Synonyms MORAb-004
Ontuxizumab (MORAb-004) is a potent IgG1/κ monoclonal antibody targeting endomelanic acid with anti-tumor effects. It specifically targets endothelin (TEM-1 or CD248) and is used for the treatment of metastatic melanoma.
Ontuxizumab
Cas No. 946415-62-9
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $297 | - | In Stock | |
| 5 mg | $788 | - | In Stock | |
| 10 mg | $1,230 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:97.91% (SDS-PAGE); 99.85% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Ontuxizumab (MORAb-004) is a potent IgG1/κ monoclonal antibody targeting endomelanic acid with anti-tumor effects. It specifically targets endothelin (TEM-1 or CD248) and is used for the treatment of metastatic melanoma. |
| In vitro | Ontuxizumab induces internalization of CD248 in a dose-dependent manner, with a reduction of 46% in surface CD248 on human dermal fibroblasts after 12 hours of treatment with concentrations ranging from 0 to 100 μg/mL[1]. |
| In vivo | In human CD248 knock-in mice, Ontuxizumab demonstrates antitumor effects when administered at a dose of 50 mg/kg via intravenous injection, given five times a day for five consecutive days[1]. |
| Synonyms | MORAb-004 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | TEM1/Endosialin/CD248 |
| Molecular Weight | 145 kDa |
| Cas No. | 946415-62-9 |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | -20°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Citations
Calculator
Keywords
Preview
Related Tags: buy Ontuxizumab | purchase Ontuxizumab | Ontuxizumab cost | order Ontuxizumab | Ontuxizumab in vivo | Ontuxizumab in vitro | Ontuxizumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.